仁度生物2025年度归母净利润950.91万元，同比扭亏为盈

Core Viewpoint - RenDu Bio (688193.SH) reported a revenue of 162 million yuan for the fiscal year 2025, reflecting a year-on-year decline of 8.62%, while achieving a net profit attributable to the parent company of 9.51 million yuan, marking a turnaround from previous losses [1] Financial Performance - The company achieved an operating income of 162 million yuan, which is a decrease of 8.62% compared to the previous year [1] - The net profit attributable to the parent company was 9.51 million yuan, indicating a return to profitability [1] Operational Strategies - During the reporting period, the company actively implemented the "Quality Improvement and Efficiency Enhancement for Returns" action plan [1] - Measures such as cost reduction and efficiency enhancement, along with expense control, contributed to a year-on-year decrease in period expenses [1] Accounts Management - The company strengthened accounts receivable management, successfully recovering some receivables from previous years [1] - According to relevant accounting standards and company policies, the company reversed some impairment losses during the reporting period [1]